\n
<\/p>\n
AI companies love to make bold claims about healthcare. Alphabet\u2019s Isomorphic<\/a> tells us that \u201cfrontier AI can unlock deeper scientific insights, faster breakthroughs, and life-changing medicines.\u201d Lila<\/a> confidently markets its AI as a tool for “faster discovery for every field where breakthrough science matters.” And they\u2019re spending as though they believe the hype. Anthropic recently acquired stealth startup Coefficient Bio<\/a> for $400 million.<\/p>\n But there’s only one true test of any healthcare AI: Did it work in humans? Did it create a medicine that saved someone’s life?<\/p>\n And bluntly, most companies have not achieved that. Let\u2019s look at the number of treatments brought to market. Isomorphic? None. Lila? The same. Marketing claims in AI rarely survive contact with reality.<\/p>\n That’s because making real progress in healthcare is hard.<\/p>\n To test a new treatment, you need to take it through a Phase 3 clinical trial. That’s typically 10 years and $2 billion. To test a diagnostic, you need to demonstrate clinical benefit, pass a rigorous third-party test, and build a full quality management system\u2014before your product is even permitted into the clinic. To uncover and prove new human biology? That could take decades of scientific experimentation.<\/p>\n So what do we need to do? The industry needs to close the gap between where AI models are trained and where medicine actually happens.<\/p>\n That hard graft is what the best AI companies in the field are doing. Companies like Insilico Medicine and Recursion are advancing AI-discovered assets through clinical trials. At Owkin, we’ve taken OKN4395, our oncology drug, into the Phase 1a clinical INVOKE trial. Beyond that, we’ve trained our AI on real patient data for years and brought MSIntuit CRC through Europe\u2019s CE mark into pathology practice.<\/p>\nCLOSE THE GAP<\/strong><\/h2>\n